The Drug Controller General of India has asked drug regulators in all states and Union territories to withdraw AstraZeneca’s anti-cancer drug Olaparib tablets for treatment in patients who have received three or more prior lines of chemotherapy. The communication stated that the firm presented the clinical evidence for the withdrawal of the indication of Olaparib tablets.